For: | Luo HY, Xu RH. Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. World J Gastroenterol 2014; 20(14): 3858-3874 [PMID: 24744578 DOI: 10.3748/wjg.v20.i14.3858] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v20/i14/3858.htm |
Number | Citing Articles |
1 |
Seon Ae Roh, In Ja Park, Yong Sik Yoon, Yi Hong Kwon, Jin Hwa Chung, Tae Won Kim, Dong Hyung Cho, Byung Ho Lim, Seon Kyu Kim, Seon Young Kim, Yong Sung Kim, Jin Cheon Kim. Feasibility of novel PPP1R15A and proposed ANXA11 single nucleotide polymorphisms as predictive markers for bevacizumab regimen in metastatic colorectal cancer. Journal of Cancer Research and Clinical Oncology 2016; 142(8): 1705 doi: 10.1007/s00432-016-2177-5
|
2 |
Suman Kumar Ray, Sukhes Mukherjee. Starring Role of Biomarkers and Anticancer Agents as a Major
Driver in Precision Medicine of Cancer Therapy. Current Molecular Medicine 2023; 23(2): 111 doi: 10.2174/1566524022666211221152947
|
3 |
Michael T. Serzan, Benjamin A. Weinberg, Mohamed E. Salem. Second-Line Therapy for Advanced Colorectal Cancer: EGFR vs. Continuation of VEGF Inhibition. Current Colorectal Cancer Reports 2017; 13(6): 411 doi: 10.1007/s11888-017-0388-z
|
4 |
Yiping Lu, Si Wu, Changwan Cui, Miao Yu, Shuang Wang, Yuanyi Yue, Miao Liu, Zhengrong Sun. <p>Gene Expression Along with Genomic Copy Number Variation and Mutational Analysis Were Used to Develop a 9-Gene Signature for Estimating Prognosis of COAD</p>. OncoTargets and Therapy 2020; : 10393 doi: 10.2147/OTT.S255590
|
5 |
Stacey Shiovitz, William M. Grady. Molecular Markers Predictive of Chemotherapy Response in Colorectal Cancer. Current Gastroenterology Reports 2015; 17(2) doi: 10.1007/s11894-015-0431-7
|
6 |
Giovanna Mirone, Arvind Shukla, Gabriella Marfe. Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer. Critical Reviews in Oncology/Hematology 2016; 97: 85 doi: 10.1016/j.critrevonc.2015.08.012
|
7 |
Vibeke Andersen, Katrine Svenningsen, Lina Almind Knudsen, Axel Kornerup Hansen, Uffe Holmskov, Allan Stensballe, Ulla Vogel. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology. World Journal of Gastroenterology 2015; 21(41): 11862-11876 doi: 10.3748/wjg.v21.i41.11862
|
8 |
Zhiqiang Cai, Fuxiang Zhou. A novel Anoikis and immune-related genes marked prognostic signature for colorectal cancer. Medicine 2022; 101(46): e31127 doi: 10.1097/MD.0000000000031127
|
9 |
Elmira Safaie Qamsari, Sepideh Safaei Ghaderi, Bahareh Zarei, Ruhollah Dorostkar, Salman Bagheri, Farhad Jadidi-Niaragh, Mohammad Hossein Somi, Mehdi Yousefi. The c-Met receptor: Implication for targeted therapies in colorectal cancer. Tumor Biology 2017; 39(5): 101042831769911 doi: 10.1177/1010428317699118
|
10 |
Yuan-Hong Xie, Ying-Xuan Chen, Jing-Yuan Fang. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduction and Targeted Therapy 2020; 5(1) doi: 10.1038/s41392-020-0116-z
|
11 |
Su-Jin Shin, Sung-Min Chun, Tae-Im Kim, Yu Jin Kim, Hyun-Jeung Choi, Se Jin Jang, Jihun Kim, Alvaro Galli. Feasibility of multiplexed gene mutation detection in plasma samples of colorectal cancer patients by mass spectrometric genotyping. PLOS ONE 2017; 12(5): e0176340 doi: 10.1371/journal.pone.0176340
|
12 |
Marina De Rosa, Daniela Rega, Valeria Costabile, Francesca Duraturo, Antonello Niglio, Paola Izzo, Ugo Pace, Paolo Delrio. The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care. Therapeutic Advances in Gastroenterology 2016; 9(6): 861 doi: 10.1177/1756283X16659790
|
13 |
Zuojing Yin, Xinmiao Yan, Qiming Wang, Zeliang Deng, Kailin Tang, Zhiwei Cao, Tianyi Qiu. Detecting Prognosis Risk Biomarkers for Colon Cancer Through Multi-Omics-Based Prognostic Analysis and Target Regulation Simulation Modeling. Frontiers in Genetics 2020; 11 doi: 10.3389/fgene.2020.00524
|
14 |
Ashraf Dallol, Abdelbaset Buhmeida, Mahmoud Shaheen Al-Ahwal, Jaudah Al-Maghrabi, Osama Bajouh, Shadi Al-Khayyat, Rania Alam, Atlal Abusanad, Rola Turki, Aisha Elaimi, Hani A. Alhadrami, Mohammed Abuzenadah, Huda Banni, Mohammed H. Al-Qahtani, Adel M. Abuzenadah. Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples. Journal of Translational Medicine 2016; 14(1) doi: 10.1186/s12967-016-0878-9
|
15 |
Sinead A. Noonan, Maria E. Morrissey, Petra Martin, Monika Biniecka, Shane Ó’Meachair, Aoife Maguire, Miriam Tosetto, Blathnaid Nolan, John Hyland, Kieran Sheahan, Diarmuid O’Donoghue, Hugh Mulcahy, David Fennelly, Jacintha O’Sullivan. Tumour vasculature immaturity, oxidative damage and systemic inflammation stratify survival of colorectal cancer patients on bevacizumab treatment. Oncotarget 2018; 9(12): 10536 doi: 10.18632/oncotarget.24276
|
16 |
Timothy W R Kelso, Devin K Porter, Maria Luisa Amaral, Maxim N Shokhirev, Christopher Benner, Diana C Hargreaves. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers. eLife 2017; 6 doi: 10.7554/eLife.30506
|
17 |
Susana G. Cárdenas-Ramos, Gregorio Alcázar-González, Luisa M. Reyes-Cortés, Abdiel A. Torres-Grimaldo, Ana L. Calderón-Garcidueñas, José Morales-Casas, Patricia Flores-Sánchez, Raúl De León-Escobedo, Antonio Gómez-Díaz, Carmen Moreno-Bringas, Jorge Sánchez-Guillén, Pedro Ramos-Salazar, César González-de León, Hugo A. Barrera-Saldaña. The Frequency and Type of K-RAS Mutations in Mexican Patients With Colorectal Cancer. American Journal of Clinical Oncology 2017; 40(3): 274 doi: 10.1097/COC.0000000000000143
|
18 |
Petra Martin, Sinead Noonan, Michael P Mullen, Caitriona Scaife, Miriam Tosetto, Blathnaid Nolan, Kieran Wynne, John Hyland, Kieran Sheahan, Giuliano Elia, Diarmuid O’Donoghue, David Fennelly, Jacintha O’Sullivan. Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer. BMC Cancer 2014; 14(1) doi: 10.1186/1471-2407-14-887
|
19 |
A. Makkouk, V. Sundaram, C. Chester, S. Chang, A.D. Colevas, J.B. Sunwoo, H. Maecker, M. Desai, H.E. Kohrt. Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy. Annals of Oncology 2017; 28(2): 415 doi: 10.1093/annonc/mdw570
|
20 |
Long Bai, Feng Wang, Dong-sheng Zhang, Cong Li, Ying Jin, De-shen Wang, Dong-liang Chen, Miao-zhen Qiu, Hui-yan Luo, Zhi-qiang Wang, Yu-hong Li, Feng-hua Wang, Rui-hua Xu. A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer. Scientific Reports 2015; 5(1) doi: 10.1038/srep17717
|
21 |
CHUNYUAN LIU, AIHONG ZHANG, LEI CHENG, YANG GAO. miR-410 regulates apoptosis by targeting Bak1 in human colorectal cancer cells. Molecular Medicine Reports 2016; 14(1): 467 doi: 10.3892/mmr.2016.5271
|
22 |
Eavan C. McLoughlin, Brendan Twamley, John E. O'Brien, Patricia Hannon Barroeta, Daniela M. Zisterer, Mary J. Meegan, Niamh M. O'Boyle. Synthesis by diastereomeric resolution, biochemical evaluation and molecular modelling of chiral 3-hydroxyl b-lactam microtubule-targeting agents for the treatment of triple negative breast and chemoresistant colorectal cancers. Bioorganic Chemistry 2023; 141: 106877 doi: 10.1016/j.bioorg.2023.106877
|
23 |
Gaia Peluso, Paola Incollingo, Armando Calogero, Vincenzo Tammaro, Niccolò Rupealta, Gaetano Chiacchio, Maria Laura Sandoval Sotelo, Gianluca Minieri, Antonio Pisani, Eleonora Riccio, Massimo Sabbatini, Umberto Marcello Bracale, Concetta Anna Dodaro, Nicola Carlomagno. Current Tissue Molecular Markers in Colorectal Cancer: A Literature Review. BioMed Research International 2017; 2017: 1 doi: 10.1155/2017/2605628
|
24 |
Nabarun Roy, P. A. Nazeem, T. D. Babu, P. S. Abida, Arunaksharan Narayanankutty, Ravisankar Valsalan, P. A. Valsala, Achuthan C. Raghavamenon. EGFR gene regulation in colorectal cancer cells by garlic phytocompounds with special emphasis on S-Allyl-L-Cysteine Sulfoxide. Interdisciplinary Sciences: Computational Life Sciences 2018; 10(4): 686 doi: 10.1007/s12539-017-0227-6
|
25 |
Eunyoung Kim, Sohee Jung, Won Seo Park, Joon-Hyop Lee, Rumi Shin, Seung Chul Heo, Eun Kyung Choe, Jae Hyun Lee, Kwangsoo Kim, Young Jun Chai. Upregulation of SLC2A3 gene and prognosis in colorectal carcinoma: analysis of TCGA data. BMC Cancer 2019; 19(1) doi: 10.1186/s12885-019-5475-x
|
26 |
Yong Lin, Qian Chen, Quan‐xing Liu, Dong Zhou, Xiao Lu, Xu‐feng Deng, Hua Yang, Hong Zheng, Yuan Qiu. High expression of DJ‐1 promotes growth and invasion via the PTEN‐AKT pathway and predicts a poor prognosis in colorectal cancer. Cancer Medicine 2018; 7(3): 809 doi: 10.1002/cam4.1325
|
27 |
Lodovico Balducci. Active listening, effective communication: the pillar of personalized medicine. Journal of Medicine and the Person 2014; 12(2): 35 doi: 10.1007/s12682-014-0180-7
|
28 |
Rui-Hua Xu, Lin Shen, Jin Li, Jian-Ming Xu, Feng Bi, Yi Ba, Li Bai, Yong-Qian Shu, Tian-Shu Liu, Yu-Hong Li, Chun-Mei Bai, Xiang-Lin Yuan, Jun Zhang, Gong Chen, Ai-Ping Zhou, Ying Yuan, Xi-Jing Wang, Xiao-Ping Qian, Yan-Hong Deng. Expert consensus on maintenance treatment for metastatic colorectal cancer in China. Chinese Journal of Cancer 2016; 35(1) doi: 10.1186/s40880-015-0067-x
|
29 |
Johanna C. Bendell, Howard Hochster, Lowell L. Hart, Irfan Firdaus, Joseph R. Mace, Joshua J. McFarlane, Mark Kozloff, Daniel Catenacci, Jessie J. Hsu, Stephen P. Hack, David S. Shames, See-Chun Phan, Hartmut Koeppen, Allen L. Cohn. A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. The Oncologist 2017; 22(3): 264 doi: 10.1634/theoncologist.2016-0223
|
30 |
Christine Koulis, Raymond Yap, Rebekah Engel, Thierry Jardé, Simon Wilkins, Gemma Solon, Jeremy D. Shapiro, Helen Abud, Paul McMurrick. Personalized Medicine—Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer. Cancers 2020; 12(4): 812 doi: 10.3390/cancers12040812
|
31 |
Svetlana Bortnik, Sharon M. Gorski. Clinical Applications of Autophagy Proteins in Cancer: From Potential Targets to Biomarkers. International Journal of Molecular Sciences 2017; 18(7): 1496 doi: 10.3390/ijms18071496
|
32 |
Nesreen H. Hafez, Noha Ezzat. Epidermal growth factor receptor expression in colorectal adenocarcinoma and their corresponding metastatic sites. Egyptian Journal of Pathology 2017; 37(2): 244 doi: 10.1097/01.XEJ.0000526543.24249.1
|
33 |
Giorgia Marisi, Emanuela Scarpi, Alessandro Passardi, Oriana Nanni, Angela Ragazzini, Martina Valgiusti, Andrea Casadei Gardini, Luca Maria Neri, Giovanni Luca Frassineti, Dino Amadori, Paola Ulivi. Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-01420-0
|
34 |
Long Bai, Feng Wang, Zhe-zhen Li, Chao Ren, Dong-sheng Zhang, Qi Zhao, Yun-xin Lu, De-shen Wang, Huai-qiang Ju, Miao-zhen Qiu, Zhi-qiang Wang, Feng-hua Wang, Rui-hua Xu. Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer. Medicine 2016; 95(51): e4531 doi: 10.1097/MD.0000000000004531
|
35 |
Vishal Das, Jatin Kalita, Mintu Pal. Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges. Biomedicine & Pharmacotherapy 2017; 87: 8 doi: 10.1016/j.biopha.2016.12.064
|
36 |
Gustaw Lech, Robert Słotwiński, Maciej Słodkowski, Ireneusz Wojciech Krasnodębski. Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. World Journal of Gastroenterology 2016; 22(5): 1745-1755 doi: 10.3748/wjg.v22.i5.1745
|